SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)
$40.77 0.07 (0.172%)
Analysed SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) News Sources
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
28-09-2026
yahoo.com
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
26-10-2026
yahoo.com
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
18-09-2026
yahoo.com
How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook
18-09-2026
yahoo.com
Why Did Supernus Pharmaceuticals (SUPN) Move Today?
19-09-2026
yahoo.com
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
21-09-2026
yahoo.com
1 Healthcare Stock Worth Your Attention and 2 We Turn Down
09-10-2026
yahoo.com
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
19-10-2026
yahoo.com
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
22-10-2026
yahoo.com
Huron Consulting stock rises on S&P SmallCap 600 addition
22-10-2026
yahoo.com
What is the current price of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)?
The current price of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) is $40.77.
SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) absolute price change since previous trading day?
The absolute price change of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) since the previous trading day is $0.07.
SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) percentage price change since previous trading day?
The percentage price change of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) since the previous trading day is 0.172%.
What is the most recent average sentiment score for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)?
The most recent average sentiment score for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)?
The most recent sentiment for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) is .
SEC-8K** Filing Available For SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.